Oncolytics Biotech Inc. Announces Initial Preclinical Data for Pelareorep in Combination with RAS Inhibitor Modalities
San Diego, CA, June 1, 2026 – Oncolytics Biotech Inc. (“the Company”), a leading biotechnology company listed on NASDAQ under the ticker ONCY, has announced the release of initial preclinical data regarding the use of its lead therapeutic candidate, pelareorep, in combination with RAS inhibitor modalities. The Company also disclosed plans for additional studies evaluating pelareorep alongside multiple RAS-targeted agents.
Key Points from the Report
- Preclinical Data Released: The Company has issued a press release detailing initial preclinical results for pelareorep when used with RAS inhibitor modalities, a combination that is generating considerable interest in the oncology field.
- Future Study Plans: Oncolytics outlined its intention to further investigate pelareorep in combination with various RAS-targeted agents, expanding the scope of its preclinical and potentially clinical research programs.
- Potential Registration and Clinical Development: The Company reiterated its belief in the mechanism of action and benefits of pelareorep as a cancer therapeutic, particularly in anal, colorectal, pancreatic, and other gastrointestinal cancers. Oncolytics also stated its goals and expectations for pelareorep’s potential registrational development path in these indications.
Potential Price-Sensitive Information for Shareholders
- Market Significance: The combination of pelareorep with RAS inhibitors addresses a high-value, high-profile target in oncology. RAS mutations are common in various cancers and are often associated with poor prognosis and resistance to therapy. Positive preclinical data in this area may increase the perceived value of pelareorep, enhance partnership opportunities, and attract investor interest.
- Pipeline Expansion: The announcement signals a strategic expansion of Oncolytics’ development pipeline into combinations with RAS-targeted therapies. This could lead to new clinical trials, collaborations with major pharmaceutical companies, and expanded market opportunities.
- Upcoming Milestones: The Company has committed to additional studies and future disclosures of clinical trial results. Milestones related to these studies could be significant catalysts for the share price, depending on data readouts and regulatory feedback.
- Regulatory and Market Risks: While the Company expresses optimism, it acknowledges that the achievement of these goals is subject to regulatory outcomes, trial execution, financial resources, access to capital markets, and broader market dynamics. Shareholders should note the inherent risks and uncertainties associated with drug development.
Details for Investors
- Security Details: Oncolytics Biotech Inc. common stock trades under the symbol ONCY on the NASDAQ Stock Market LLC. The company is incorporated in Nevada and headquartered in San Diego, California.
- Company Contact:
Jon Patton
Director of IR & Communication
[email protected] - Management: The report is signed by Kirk Look, Chief Financial Officer, on behalf of the Company.
Forward-Looking Statements
This announcement contains forward-looking statements regarding the development, mechanism of action, and clinical potential of pelareorep, including its use in combination with RAS inhibitor modalities. There can be no assurance that the expected results, milestones, or registration pathways will be achieved. Actual results may differ materially due to risks and uncertainties, including regulatory outcomes, trial execution, and market factors. The Company does not undertake to update forward-looking statements except as required by law.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult their financial advisors before making investment decisions. The information contained herein is based on publicly available filings and press releases as of June 1, 2026, and may be subject to change without notice.
